Sutro Biopharma (STRO) Expected to Announce Earnings on Monday

Sutro Biopharma (NASDAQ:STRO) will likely be posting its quarterly earnings results before the market opens on Monday, March 24th. Analysts expect Sutro Biopharma to post earnings of ($0.86) per share and revenue of $12.18 million for the quarter.

Sutro Biopharma (NASDAQ:STRO) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($2.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($2.10). Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. The company had revenue of $14.00 million for the quarter, compared to analyst estimates of $10.44 million. During the same period in the prior year, the company earned ($1.78) EPS. On average, analysts expect Sutro Biopharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Sutro Biopharma Stock Performance

STRO opened at $0.81 on Monday. Sutro Biopharma has a 1 year low of $0.81 and a 1 year high of $6.13. The company’s 50 day simple moving average is $1.75 and its 200 day simple moving average is $2.72. The stock has a market capitalization of $66.80 million, a PE ratio of -0.50 and a beta of 1.22.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. JMP Securities reaffirmed a “market outperform” rating and issued a $17.00 price objective on shares of Sutro Biopharma in a research note on Wednesday, December 11th. Wedbush lowered shares of Sutro Biopharma from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $8.00 to $2.00 in a report on Friday. Wells Fargo & Company lowered their price target on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating for the company in a report on Wednesday, December 11th. Citizens Jmp cut Sutro Biopharma from an “outperform” rating to a “market perform” rating in a research note on Friday. Finally, Bank of America downgraded Sutro Biopharma from a “buy” rating to an “underperform” rating and dropped their target price for the company from $11.00 to $1.00 in a report on Friday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Sutro Biopharma currently has a consensus rating of “Hold” and a consensus target price of $9.00.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.